We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diseases Diagnosed by Isolating Biomarkers in Tears

By LabMedica International staff writers
Posted on 25 Jul 2022
Print article
Image: The NanoSight NS300 can visualize and measure particles in suspension in terms of size, light scattering intensity, fluorescence and count (Photo courtesy of Mark Wainwright Analytical Centre)
Image: The NanoSight NS300 can visualize and measure particles in suspension in terms of size, light scattering intensity, fluorescence and count (Photo courtesy of Mark Wainwright Analytical Centre)

Current clinical studies pose significant challenges in distinguishing disease subtypes with accurate molecular signatures and tracking the disease progression in a non-invasive way. Identifying molecular clues in samples from patients, such as specific proteins or genes from vesicular structures called exosomes, could improve the accuracy of diagnoses.

Since small extracellular vesicles (sEVs, exosomes) reveal specific functions in various biological processes, including immune regulation, angiogenesis, tumor invasion, and cell migration, exosome-based liquid biopsy technology has offered an attractive alternative to disease classification and prognostic prediction. Tears are well-suited for sample collection because the fluid can be collected quickly and non-invasively.

Medial Scientists at the Wenzhou Medical University (Wenzhou, China) and their colleagues carried out a retrospective case-controlled study that included patients with dry eye and type 2 diabetes. A tear sample was collected by placing a Schirmer paper on each eye, and the moistened length was immediately recorded after 5 minutes of collection or at completion (length reaching at 30 mm in 5 minutes).

The tear mixture was eluted from the Schirmer strip by shaking at 4 °C for 30 minutes and two-step centrifugation (200g for 10 minutes and 3,000g for 10 minutes) to remove cells and other impurities. Exosomes were subsequently purified with the rapid-isolation system under the negative pressure of 40 kPa and conversion time of 30 seconds, respectively. Samples were loaded to the equilibrated size exclusion chromatography column (qEV original, IZON Science Ltd., Oxford, UK), and 16 sequential fractions of 0.5 mL were eluted by adding PBS. The eluted fractions 8–10 were pooled and concentrated to a final volume of 150 μL. Nanoparticle Tracking Analysis (NTA) was performed on a NanoSight NS300 system (Malvern Panalytical, Malvern, UK). Other methods included in the study were Western Blot analysis, on-device exosome detection, proteomic analysis, and exosomal miRNA sequencing.

The investigators successfully distinguished between healthy controls and patients with various types of dry eye disease based on a proteomic assessment of extracted proteins. Similarly, the Incorporated Tear Exosomes Analysis via Rapid-isolation System (iTEARS) enabled the team to observe differences in microRNAs between patients with diabetic retinopathy and those that didn't have the eye condition, suggesting that the system could help track disease progression. The team says that this work could lead to a more sensitive, faster and less invasive molecular diagnosis of various diseases, using only tears.

The authors concluded that they established the iTEARS for deciphering the biomarkers of diseases from a teardrop, which revealed the promising role of tear exosomes in disease classification and course monitoring of ocular disorders and other diseases such as neurodegenerative diseases and cancer. By being applied in extended disease types and validated with abundant clinical cases, they anticipate their teardrop-based iTEARS to be the alternative tool for point-of-care-test. The study was published on July 20, 2022 in the journal ACS Nano.

Related Links:
Wenzhou Medical University 
IZON Science Ltd 
Malvern Panalytical

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.